title: [Expression of glypican-3, hepatocyte antigen, alpha-fetoprotein, CD34 and CD10 in hepatocellular carcinoma: a clinicopathologic analysis of 375 cases].
abstract: OBJECTIVE
  To explore prognostic factors and the expression of glypican-3, hepatocyte antigen (HEP), alpha-fetoprotein (AFP), CD34 and CD10 in hepatocellular carcinoma (HCC) and their prognostic value.
  
  
  METHODS
  Clinicopathologic data were analyzed in 375 cases of HCC, in which 80 cases with follow-up were examined by immunohistochemical staining to detect the expression of glypican-3, HEP, AFP, CD34 and CD10 proteins. The relationship between the proteins expression and clinicopathologic features was also evaluated.
  
  
  RESULTS
  Tumor number (P = 0.000), tumor size (P = 0.025), tumor differentiation (P = 0.001) and vessel invasion (P = 0.000) were closely related to prognosis of HCC patients; the expression of glypican-3 (66/80,82.5%; P = 0.002), HEP (64/80,80.0%; P = 0.021), AFP (38/80,47.5%; P = 0.014) and CD10 (28/80,35.0%; P = 0.002) was significantly related to tumor differentiation; that of glypican-3 was significantly correlated with tumor number and presence of satellite nodules (P = 0.028) and that of AFP and CD10 was significantly correlated with portal vein thrombi (P = 0.000, P = 0.010). On Kaplan-Meier regression analysis, both low expression of HEP and high expression of AFP were closely related to poor prognosis.
  
  
  CONCLUSIONS
  Tumor number, size, differentiation and vessel invasion were important factors affecting the prognosis of patients with HCC. HEP and AFP have prognostic significance in HCC.
authors.affiliation: Department of Pathology, General Hospital of People's Liberation Army, Beijing 100853, China.
authors.forename: Jing-li
authors.initials: JL
authors.lastname: Du
authors.forename: Yu-lan
authors.initials: YL
authors.lastname: Wang
authors.forename: Huai-yin
authors.initials: HY
authors.lastname: Shi
authors.forename: Ai-tao
authors.initials: AT
authors.lastname: Guo
authors.forename: Li-xin
authors.initials: LX
authors.lastname: Wei
mesh_terms: D000941:Antigens / Q000378:metabolism*; D018952:Antigens, CD34 / Q000378:metabolism; D014408:Biomarkers, Tumor / Q000378:metabolism; D006528:Carcinoma, Hepatocellular / Q000378:metabolism* / Q000473:pathology* / Q000601:surgery; D002454:Cell Differentiation; D005260:Female; D005500:Follow-Up Studies; D053673:Glypicans / Q000378:metabolism; D022781:Hepatocytes / Q000276:immunology; D006801:Humans; D008113:Liver Neoplasms / Q000378:metabolism* / Q000473:pathology* / Q000601:surgery; D008297:Male; D015260:Neprilysin / Q000378:metabolism; D011169:Portal Vein / Q000473:pathology; D011379:Prognosis; D015996:Survival Rate; D047368:Tumor Burden; D020246:Venous Thrombosis / Q000209:etiology / Q000473:pathology; D000509:alpha-Fetoproteins / Q000378:metabolism*
chemical_list: D000941:Antigens; D018952:Antigens, CD34; D014408:Biomarkers, Tumor; D053673:Glypicans; D000509:alpha-Fetoproteins; D015260:Neprilysin